Improving eligibility criteria for Alzheimer's trials using real-world data and AI
Official title: Eligibility criteria design for Alzheimer's trials with real-world data and explainable AI
Funded at Weill Medical Coll of Cornell Univ · NIH-10991018 · Data updated 2026-11-12
This study is looking to make it easier for people with Alzheimer's to join clinical trials by using real-world data to find the best candidates, so new treatments can be more effective and safe for everyone.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | February 1, 2023 |
| Project end | November 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $692,551 |
| NIH project number | 5R01AG080991-03 |
| Project ID | NIH-10991018 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease who may not typically meet the stringent eligibility criteria of current clinical trials.
✕Less likely to help
Patients who are not diagnosed with Alzheimer's disease or who are in very advanced stages of the disease may not benefit from this research.
What this research studies
This research aims to enhance the design of eligibility criteria for Alzheimer's clinical trials by utilizing real-world data and explainable artificial intelligence. It addresses the challenge of ensuring that trial participants accurately represent the broader population of Alzheimer's patients, which is crucial for the effectiveness and safety of new treatments. By analyzing electronic health records and other data sources, the project seeks to identify characteristics that can help select the most appropriate candidates for trials, ultimately improving the relevance and success of these studies. The approach combines advanced data science techniques with clinical insights to create a more inclusive and representative trial environment.
Why it matters
Potential benefit: If successful, this research could lead to more effective Alzheimer's treatments by ensuring that clinical trials include a diverse and representative patient population.
How similar studies have gone: Previous research has shown that using real-world data and AI can improve trial design and patient selection, indicating a promising avenue for enhancing Alzheimer's clinical trials.
Where this research is happening
-
Weill Medical Coll of Cornell Univ
New York, United States Active
Researchers
- Principal investigator: Wang, Fei — Weill Medical Coll of Cornell Univ
- Study coordinator: Wang, Fei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.